<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03059823</url>
  </required_header>
  <id_info>
    <org_study_id>INCMGA 0012-101</org_study_id>
    <nct_id>NCT03059823</nct_id>
  </id_info>
  <brief_title>A Phase 1 Study of INCMGA00012 in Patients With Advanced Solid Tumors</brief_title>
  <official_title>A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of INCMGA00012 in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Incyte Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Incyte Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary goal of this Phase 1 study is to characterize the safety and tolerability of
      INCMGA00012 and establish the maximum tolerated dose (MTD) of INCMGA00012 administered on
      either every two week or every four week schedules of administration among patients with
      solid tumors. Pharmacokinetics, pharmacodynamics, and the anti-tumor activity of INCMGA00012
      will also be assessed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, multi-center, Phase 1 dose-escalation and dose expansion study to
      define a MTD, describe preliminary safety, and to assess PK, immunogenicity, and potential
      anti-tumor activity of INCMGA00012 administered on either every two week or every four week
      schedules in patients with relapsed/ refractory or unresectable locally/ advanced or
      metastatic solid tumors.

      In the initial phase of the study, two dose schedules will be assessed in dose escalation,
      once every two weeks and once every four weeks administration of single agent INCMGA00012.
      Following the establishment of an MTD, additional patients will enroll in expansion cohorts
      of specific tumor types and/or INCMGA00012 dose.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 2016</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events as assessed by CTCAE v4.03</measure>
    <time_frame>24 months</time_frame>
    <description>Safety is based on evaluation of adverse events (AEs) and serious adverse events (SAEs) from the time of study drug administration through the End of Study visit.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MTD</measure>
    <time_frame>24 months</time_frame>
    <description>Maximum Tolerated Dose of INCMGA00012</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC</measure>
    <time_frame>24 months</time_frame>
    <description>Area Under the Plasma Concentration versus Time Curve of INCMGA00012</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>24 months</time_frame>
    <description>Maximum Plasma Concentration of INCMGA00012</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>24 months</time_frame>
    <description>Time to reach maximum (peak) plasma concentration of INCMGA00012</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ctrough</measure>
    <time_frame>24 months</time_frame>
    <description>Trough plasma concentration of INCMGA00012</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total body clearance of the drug from plasma (CL) of INCMGA00012</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vss</measure>
    <time_frame>24 months</time_frame>
    <description>Apparent volume of distribution at steady state of INCMGA00012</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2</measure>
    <time_frame>24 months</time_frame>
    <description>Terminal half-life of INCMGA00012</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ADA</measure>
    <time_frame>24 months</time_frame>
    <description>Percent of patients with anti-drug antibody</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">207</enrollment>
  <condition>Locally Advanced Solid Tumors</condition>
  <condition>Metastatic Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Dose Escalation-Q2W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>INCMGA00012 treatment once every 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Escalation- Q4W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>INCMGA00012 treatment once every 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Expansion Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>INCMGA00012 treatment for locally advanced or metastatic solid tumors</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INCMGA00012</intervention_name>
    <description>Anti-PD-1 monoclonal antibody</description>
    <arm_group_label>Dose Escalation-Q2W</arm_group_label>
    <arm_group_label>Dose Escalation- Q4W</arm_group_label>
    <arm_group_label>Expansion Cohort</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically proven, locally advanced unresectable or metastatic solid tumors for
             whom no approved therapy with demonstrated clinical benefit is available or standard
             treatment was declined.

          -  Expansion cohort(s): Progression during or following at least 1, and up to 5, previous
             systemic therapies, consistent with the standard of care for the specific tumor type.

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

          -  Life expectancy â‰¥ 12 weeks

          -  Measurable disease

          -  Acceptable laboratory parameters

        Exclusion Criteria:

          -  Symptomatic central nervous system (CNS) metastases.

          -  For Cohort Expansion, patients who have previously received an immune checkpoint
             inhibitor (e.g., anti-PD-L1, anti-PD-1, anti-CTLA-4) are not eligible for this study.

          -  Patients with any history of known or suspected autoimmune disease with the specific
             exceptions of vitiligo, resolved childhood atopic dermatitis, psoriasis not requiring
             systemic treatment (within the past 2 years), and patients with a history of Grave's
             disease that are now euthyroid clinically and by laboratory testing.

          -  Treatment with any systemic anti-neoplastic therapy, or investigational therapy within
             the 4 weeks prior to the initiation of study drug administration.

          -  Treatment with radiation therapy within 2 weeks prior to the initiation of study drug
             administration.

          -  Clinically significant cardiovascular disease

          -  Clinically significant pulmonary compromise, including a requirement for supplemental
             oxygen use to maintain adequate oxygenation.

          -  Presence of active pneumonitis or history of non-infectious pneumonitis.

          -  Clinically significant gastrointestinal disorders

          -  Evidence of active viral, bacterial, or systemic fungal infection requiring parenteral
             treatment within 7 days prior to the initiation of study drug. Patients requiring any
             systemic antiviral, antifungal, or antibacterial therapy for active infection must
             have completed treatment no less than one week prior to the initiation of study drug

          -  Known history of positive testing for human immunodeficiency virus or history of
             acquired immune deficiency syndrome.

          -  Known history of hepatitis B or hepatitis C infection or known positive test for
             hepatitis B surface antigen, hepatitis B core antigen, or hepatitis C polymerase chain
             reaction (PCR)

          -  Vaccination with any live virus vaccine within 4 weeks prior to the initiation of
             study drug administration. Inactivated annual influenza vaccination is allowed

          -  Dementia or altered mental status that would preclude understanding and rendering of
             informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Incyte Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Incyte Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Incyte Corporation Call Center (US)</last_name>
    <phone>1.855.463.3463</phone>
    <email>medinfo@incyte.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Incyte Corporation Call Center (ex-US)</last_name>
    <phone>+800 00027423</phone>
    <email>globalmedinfo@incyte.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>HonorHealth Research Institute - Pima</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>START Midwest, LLC</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49546</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rutgers Cancer Institute of New Jersey</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Carolina BioOncology Institute</name>
      <address>
        <city>Huntersville</city>
        <state>North Carolina</state>
        <zip>28078</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>START - South Texas Accelerated Research Therapeutics, LLC</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Massey Cancer Center VCU</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St Vincent's Hospital Sydney</name>
      <address>
        <city>Sydney</city>
        <zip>02010</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chris O'Brien Lifehouse</name>
      <address>
        <city>Sydney</city>
        <zip>02050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MHAT&quot; Nadezhda&quot;, Department of Medical Oncology</name>
      <address>
        <city>Sofia</city>
        <zip>01330</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CharitÃ© Comprehensive Cancer Center (CCCC)</name>
      <address>
        <city>Berlin</city>
        <zip>12203</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum der UniversitÃ¤t MÃ¼nchen - Campus GroÃŸhadern</name>
      <address>
        <city>Muenchen</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>StÃ¤dtische Klinikum MÃ¼nchen - Neuperlach, Klinik fÃ¼r HÃ¤matologie und Onkologie</name>
      <address>
        <city>Muenchen</city>
        <zip>81737</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Auckland City Hospital</name>
      <address>
        <city>Auckland</city>
        <zip>01023</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Wellington Hospital</name>
      <address>
        <city>Wellington</city>
        <zip>06021</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Szpitale Pomorskie Sp. z o.o., OddziaÅ‚ Onkologii i Radioterapii</name>
      <address>
        <city>GdaÅ„sk</city>
        <zip>80-219</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Department of Oncology, University Hospital in Kracow</name>
      <address>
        <city>KrakÃ³w</city>
        <zip>31-501</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>KO-MED Centra Kliniczne, OÅ›rodek BadaÅ„ Klinicznych w Lublinie</name>
      <address>
        <city>Lublin</city>
        <zip>20-362</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>BioVirtus Research Site Sp. Z o.o.</name>
      <address>
        <city>Otwock</city>
        <zip>05-400</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Szpital Kliniczny Przemienienia PaÅ„skiego Uniwersytetu Medycznego im. Karola Marcinkowskiego w Poznaniu</name>
      <address>
        <city>PoznaÅ„</city>
        <zip>60-569</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Maria SkÅ‚odowska Curie Memorial Cancer Centte and Institute of Oncology</name>
      <address>
        <city>Warsaw</city>
        <zip>02-789</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>START Madrid-CIOCC, Hospital HM Sanchinarro</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital #4, Department of Oncology affiliated with State Medical Academy</name>
      <address>
        <city>Dnipro</city>
        <zip>49102</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regional Clinical Oncology Center, Department of Chemotherapy in the facility of State Higher Educational Institution</name>
      <address>
        <city>Ivano-Frankivs'k</city>
        <zip>76000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sumy clinical oncological dispensary</name>
      <address>
        <city>Sumy</city>
        <zip>04003</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Department of oncology and radiology Uzhgorod National University</name>
      <address>
        <city>Ãšzhgorod</city>
        <zip>08800</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sarah Canon Research Institute</name>
      <address>
        <city>London</city>
        <zip>W1G 6AD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Drug Development Unit, Sycamore House, The Royal Marsden NHS Foundation Trust</name>
      <address>
        <city>Sutton</city>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Bulgaria</country>
    <country>Germany</country>
    <country>New Zealand</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 9, 2017</study_first_submitted>
  <study_first_submitted_qc>February 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 23, 2017</study_first_posted>
  <last_update_submitted>April 11, 2018</last_update_submitted>
  <last_update_submitted_qc>April 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Solid tumors</keyword>
  <keyword>Metastatic cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

